October 26, 2020 8:09am

Today begins the last week of October, the final trading period before Nov. 3 and the sector’s earnings’ release ramp-up

Pre-open indications: gravity is a force that attracts bottoms

What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times

 

Dow futures are DOWN -0.97% (-274 points), S&P futures are DOWN -0.89% (-31 points) and NASDAQ futures are DOWN -0.77% (-90 points)

 

Futures fell on Monday as coronavirus infections jumped and negotiations for a stimulus package before the election turned down;

European markets were lower as coronavirus cases surged throughout the continent weighed on sentiment;

Asia Pacific markets were mixed as investors monitored the deteriorating situation in the West;

 

Henry’omics:

The decline in futures came amid a record surge in new coronavirus cases in the U.S. The country saw more than 83,000 new infections on both Friday and Saturday after outbreaks in Sun Belt states, surpassing a previous record of roughly 77,300 cases set in July, according to data from Johns Hopkins University.

The Dow fell on Friday to end a downbeat week as investors weighed the probabilities for additional fiscal stimulus.

 

Friday night’s post: RegMed Investors’ (RMi) closing bell: “waiting for “prospects” of coronavirus aid to be pushed through …  https://www.regmedinvestors.com/articles/11603  

  • The Nasdaq closed UP +42.28 points (+0.37%);
  • The IBB closed up +0.25% and XBI closed up +0.50%;
  • Sector volume was the usual LOW with 7 of the 24-upside having higher than the 3-month average volume with the increased volume of 2 of 10-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.56 points or -`1.99% at 27.55;
  • Friday’s percentage (%) of the 24-upside were +0.04% (BLUE) to +10.64% (SLDB) while the 10-downside ranges from -0.18% (FIXX) to -8.15% (MDXG);

Q4’s October, so far: 1 neutral, 9 positive and 7 negative closes

Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

 

Companies in my headlights – It’s your decision; I provide an idea and context:

I am share pricing … AGNOSTIC … today although … Maintaining Sell:

Biostage (BSTG) closed down -$0.07 to $1.36 after Thursday’s +$0.07 to $1.43 with 1,035, Wednesday’s flat at $1.36 with 42 shares traded, Tuesday’s -$0.14 to $1.36 with 5,354 shares traded following last Monday’s flat at $1.50.  

  • Question#1: WHY does RSM US, LLP BSTG’s auditor write so much about their processes without siting ANY standards of practice, rules, guidelines and standards in their audit of BSTG?
  •  Question#2: Is RSM US practicing HOW the “Public company Accounting Oversight Board is driving their work/process in their audit where standard SEC govern rules about (BSTG) their client?
  • Question#3: Wonder WHY do I maintain a SELL rating and such a negative regard about the company?
  • Question#4: HOW many … daily, weekly, monthly and quarterly reports over eleven (11) months to Jason Chen, chairman of the board does it or take to VALIDATE the ranking?
  • Question#5: WHO was it that was brought to assist the then CEO in a new “wind” (certainly was not Hong Yu, current president) to “facilitate and ultimately redo” the IND with its ultimate approval?

 

The BOTTOM LINE: New and last week of the month of October. Investors should be BRACING for quarterly (Q3) earnings’ releases.

The firing range is open and the wind flag is measuring the wind speed which can be converted into lateral minute of angle point of BUY or SELL corrections or, holdoff corrections.

The clock is ticking … I am share pricing … AGNOSTIC … today!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.